Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): NIMH Study To Guide Treatment Choices for Schizophrenia
Older Medication May Be More Cost-Effective for Some Patients with Schizophrenia
A new study analyzing the economic implications of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) concludes that the older (first generation) antipsychotic medication perphenazine was less expensive and no less effective than the newer (second generation) medications used in the trial during initial treatment, suggesting that older antipsychotics still have a role in treating schizophrenia. The study, published in the American Journal of Psychiatry on December 1, 2006, was funded by the National Institutes of Health’s National Institute of Mental Health (NIMH).
Questions and Answers
- Questions and Answers about the NIMH Clinical Antipsychotic Trials of Intervention Effectiveness Study (CATIE) — Phase 2 Results, Published April 1, 2006
- Questions and Answers about the NIMH Clinical Antipsychotic Trials of Intervention Effectiveness Study (CATIE) — Phase 1 Results
Related Information
- Press Release: Studies Offer New Information About Treatment Choices for Schizophrenia (Phase 2 Results)
- Press Release: NIMH Study To Guide Treatment Choices for Schizophrenia (Phase 1 Results)
- NIMH Schizophrenia Page
- Director’s Update: NIMH Perspective on Antipsychotic Reimbursement: Using Results from CATIE
- Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) from ClinicalTrials.gov
- Web Forum Launched for Schizophrenia Researchers